Treximo

The treatment of glioblastomas remains extremely challenging. However, Glioblastoma brain tumors have been shown to have receptors to cannabinoids on their cell surfaces, that's why the University of Leeds (UK) will run a Phase-II trial using a cannabis-based drug, Sativex, for treating these aggressive brain tumors: https://bit.ly/2WEE3gM

University of Leeds to assess cannabis-based drug for brain tumours The University of Leeds is set to lead a Phase II trial to evaluate the use of a cannabis-based drug, Sativex, for aggressive brain tumours.

AstraZeneca's drug Saphnelo for the treatment of Systemic Lupus wins FDA approval. This is the first drug approved since 2011 for this disease: https://bit.ly/3ysjNML

AstraZeneca wins first FDA approval for systemic lupus drug in a decade The regulator cleared Saphnelo despite mixed clinical trial data, giving patients another option after the recent OK for a drug aimed at the autoimmune disease's severe side effects.

A change in management is always a big challenge, especially in life-science companies. Treximo has experience with Top pharmaceutical companies to lead these processes and achieve the desired results that can also be applied to your company when needed.

Get to know how we help life-science companies with Clinical Monitoring Change Management here: https://treximo.com/blog/case-study/clinical-monitoring-change-management/